Jenny F. Seligmann - Concepedia

Author

Jenny F. Seligmann

University of Leeds ORCID

Also Known As

J Taeb, J. Seligmann, J.F. Seligmann, Jenny F Seligmann, Jenny F. Seligmann, Jenny Seligmann, Seligmann, JF

150

Publications

Citations

H-Index

Concepts

All Affiliations

University of Leeds St James's University Hospital University of Oxford University College London University of Birmingham

About

Jenny F. Seligmann is an author at University of Leeds specializing in oncology, medicine, and colorectal cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	1.8K
2	Gastroenterology	4	4	1.7K
3	Health Sciences	2	2	45
4	Health Policy	1	1	21
5	Immunology	1	1	26

Jenny F. Seligmann

Publications

2.5K

Citations

H-Index

Page 1

	Year	Citations
Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Andrés Cervantes, R. Adam, Susana Roselló, Annals of Oncology Surgical OncologyGastrointestinal OncologyMedicineCancer ManagementGastroenterology	2022	1.4K
Preoperative Chemotherapy for Operable Colon Cancer: Mature Results of an International Randomized Controlled Trial Dion Morton, Laura Magill, Kelly Handley, Journal of Clinical Oncology	2023	387
Investigating the poor outcomes ofBRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials Jenny F. Seligmann, David J. Fisher, Christopher G. Smith, Annals of Oncology MedicineCancer ManagementRandomised Clinical TrialsGastroenterologyPathology	2016	163
Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With<i>RAS</i>Wild-Type Advanced Colorectal Cancer Jenny F. Seligmann, Faye Elliott, Susan D. Richman, JAMA Oncology	2016	105
Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS , and NRAS (FOCUS4-D): a phase 2–3 randomised trial Richard Adams, Ewan Brown, Louise Brown, The Lancet. Gastroenterology & hepatology	2017	55
FOxTROT: neoadjuvant FOLFOX chemotherapy with or without panitumumab (Pan) for patients (pts) with locally advanced colon cancer (CC). Jenny F. Seligmann Journal of Clinical Oncology Surgical OncologyCancer ManagementGastroenterologyPathologyPan Randomisation	2020	34
<i>EGFR</i>Amplification in Metastatic Colorectal Cancer Giovanni Randon, Rona Yaeger, Jaclyn F. Hechtman, JNCI Journal of the National Cancer Institute	2021	32
Association of Tumor <i>HER3</i> Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal Cancer Jenny F. Seligmann, Ace J. Hatch, Susan D. Richman, JAMA Oncology	2017	29
NEOPRISM-CRC: Neoadjuvant pembrolizumab stratified to tumour mutation burden for high risk stage 2 or stage 3 deficient-MMR/MSI-high colorectal cancer. Kai‐Keen Shiu, Yanrong Jiang, Mark Saunders, Journal of Clinical Oncology Surgical OncologyImmunologyPathologyNeoadjuvant PembrolizumabImmunotherapy	2024	26
Making an IMPACT: A priority setting consultation exercise to improve outcomes in patients with locally advanced, recurrent and metastatic colorectal cancer Abigail Vallance, Deena Harji, Nicola Fearnhead, European Journal of Surgical Oncology Palliative CareSurgical OncologyHealth PolicyMedicineCancer Management	2019	21

Page 1